Key result
Empagliflozin suppresses ventricular arrhythmias in diabetic cardiomyopathy by normalizing intracellular calcium handling.
Why the study?
The mechanism by which selective SGLT2 inhibitors suppress ventricular arrhythmia in diabetic cardiomyopathy remains unclear despite their known cardioprotective effects.
Does empagliflozin prevent ventricular arrhythmia in diabetic model mice?
Does empagliflozin prevent ventricular arrhythmia in diabetic model mice?
Empagliflozin may suppress ventricular arrhythmias in diabetic cardiomyopathy by normalizing intracellular calcium handling via inhibition of O-GlcNAc modification.
Answers are grounded in this paper and cite their sources.
Supports mechanistic antiarrhythmic effects in diabetic models; hypothesis-generating and requires clinical validation before practice change.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
A 2025 study conducted a review in Diabetic cardiomyopathy. Empagliflozin vs. Control (no empagliflozin) was evaluated on Ventricular arrhythmia inducibility (PVCs and arrhythmia score). Empagliflozin attenuated ventricular arrhythmias in a diabetic cardiomyopathy mouse model by suppressing O-GlcNAcylation and normalizing intracellular calcium handling.
Synapse has enriched 10 related papers. Consider them for comparative context: